Antonio Gil-Nagel. Programa de epilepsia Hospital Ruber Internacional, Madrid. Centro de Tecnología Biomédica Universidad Politécnica de Madrid

Similar documents
Cross Border Genetic Testing for Rare Diseases

WCPT COUNTRY PROFILE December 2017 HUNGARY

WCPT COUNTRY PROFILE December 2017 SWEDEN

Overview of drug-induced deaths in Europe - What does the data tell us?

Smokefree Policies in Europe: Are we there yet?

WCPT COUNTRY PROFILE December 2017 SERBIA

Prevention via Modifiable Risk Factors Saturday, June 23, 2012

All patients with a diagnosis of treatment resistant (intractable) epilepsy.* Denominator Statement

The health economic landscape of cancer in Europe

Standards of Care in Epilepsy Current Access to Basic Epilepsy Care Across the European Union

European Collaboration on Dementia. Luxembourg, 13 December 2006

UK bowel cancer care outcomes: A comparison with Europe

Monthly measles and rubella monitoring report

European Status report on Alcohol and Health

Inequalities in health: challenges and opportunities in Europe Dr Zsuzsanna Jakab WHO Regional Director for Europe

PARALLELISM AND THE LEGITIMACY GAP 1. Appendix A. Country Information

Estimating Smoking Related Cause of Death: a Cohort Approach Based on Lung Cancer Mortality in six European Countries

The cancer burden in the European Union and the European Region: the current situation and a way forward

Cost of Disorders of the Brain in Europe Gustavsson et al. Cost of disorders of the brain in Europe Eur. Neuropsych. (2011) 21,

Yersiniosis SURVEILLANCE REPORT. Annual Epidemiological Report for Key facts. Methods. Epidemiology

Biology Report. Is there a relationship between Countries' Human Development Index (HDI) level and the incidence of tuberculosis?

Burden and cost of alcohol, tobacco and illegal drugs globally and in Europe

REPORT FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT, THE COUNCIL, THE EUROPEAN ECONOMIC AND SOCIAL COMMITTEE AND THE COMMITTEE OF THE REGIONS

Q1 What age are you?

Alcohol in Europe and Brief Intervention. Dr Lars Møller Programme Manager World Health Organization Regional Office for Europe

Trichinellosis SURVEILLANCE REPORT. Annual Epidemiological Report for Key facts. Methods

Alcohol-related harm in Europe and the WHO policy response

Men & Health Work. Difference can make a difference Steve Boorman & Ian Banks RSPH Academy 2013

TEDDY. Teddy Network of Excellence. Annagrazia ALTAVILLA. Ph.D. Sciences Ethics LL.M. Health Law. diterranée

THE CVD CHALLENGE IN NORTHERN IRELAND. Together we can save lives and reduce NHS pressures

The Role of a Vascular Surgeon in the Treatment of Drug Resistant Epilepsy

LEBANON. WCPT COUNTRY PROFILE December 2018

ALCOHOL CONSUMPTION IN EUROPE; TRADITIONS, GENERATIONS, CULTURE AND POLICY

Real Life, Real PD Survey

What do we know about prognosis and natural course of epilepsies?

Is there a relationship between Countries' Human Development Index (HDI) level and the incidence of tuberculosis?

DENMARK. WCPT COUNTRY PROFILE December 2018

Epilepsy. Seizures and Epilepsy. Buccal Midazolam vs. Rectal Diazepam for Serial Seizures. Epilepsy and Seizures 6/18/2008

CNAPA Meeting Luxembourg September 2016

Rheumatoid Arthritis Disease Burden and Access to Treatment

real-time AQ data 2007 and plans for 2008

Perspectives for information on alcohol use in the EU

GERMANY. WCPT COUNTRY PROFILE December 2018

Engagement in language assessment / Regions of Europe

Screening for Cervical Cancer in Europe

Critical immunity thresholds for measles elimination

Who is a migrant? 12/10/2018. HIV and migrants. Heterogeneous groups of persons with different migration drivers

The Utilization of Epilepsy Surgery Potential Gaps and Future Directions

Outcome of proficiency test on EIA serology

A report on the epidemiology of selected vaccine-preventable diseases in the European Region 30% 20% 10%

Drinking guidelines used in the context of early identification and brief interventions in Europe: overview of RARHA survey results

Primary and secondary prevention of sudden cardiac death in emerging economies

Emerging Risks Mapping of Activities in Member States. 67th Advisory Forum meeting, Utrecht, The Netherlands, 6 February 2018

Epilepsies of Childhood: An Over-view of Treatment 2 nd October 2018

Manuel Cardoso RARHA Executive Coordinator Public Health MD Senior Advisor Deputy General-Director of SICAD - Portugal

Project Meeting Prague

Underage drinking in Europe

National Institute on Alcohol Abuse and Alcoholism. Environmental Approaches

Summary of Results for Laypersons

Where we stand in EFORT

State of provision of Hearing Aids in Europe

Identifying Europe s information needs for effective drug policy Lisbon, EMCCDA

European Partnership for Screening

Global Trade in Lightweight Coated Writing Paper TradeData International Pty Ltd ( Page 1 5/18/2015

The Risk of Alcohol in Europe. Bridging the Gap June 2004

On behalf of E-PILEPSY consortium Philippe Ryvlin (Lyon, France)

Current levels and recent trends in health inequalities in the EU: Updates from the EU Report

Media Release. Inaugural study reveals that more than one in four women in European and Central Asian prisons locked up for drug offences

Present and potential perspectives for information on alcohol use in the EU

Access to treatment and disease burden

The Current Status of Cardiac Electrophysiology in ESC Member Countries J. Brugada, P. Vardas, C. Wolpert

D7.1 Report summarising results of survey of EU countries to identify volumes and trends in relation to the import and export of stem cells

Where do EU Contries set the limit for low risk drinking.

D7.1 Report summarising results of survey of EU countries to identify volumes and trends in relation to the import and export of stem cells

European status report on alcohol and health Leadership, awareness and commitment

COMMISSION OF THE EUROPEAN COMMUNITIES

31 countries (117 registries, 20 national) Increased coverage in countries with regional registries 50% European population Overall >20 million

The young ophthalmologist Assuming the challenge. Stefan Seregard

Cancer drug costs and payment issues in European countries.

New trends in harm reduction in Europe: progress made challenges ahead

PLACEMENT AND TREATMENT OF MENTALLY ILL OFFENDERS LEGISLATION AND PRACTICE IN EU-MEMBER STATES

Finnish international trade 2017 Figures and diagrams. Finnish Customs Statistics

Multidrug- and extensively drug-resistant tuberculosis: a persistent problem in the European Union European Union and European Economic Area

Finnish international trade 2017 Figures and diagrams. Finnish Customs Statistics

The Identification of Food Safety Priorities using the Delphi Technique

IOSH No Time to Lose campaign: working together to tackle asbestos-related cancer #NTTLasbestos. Jonathan Hughes IOSH Vice President

Sign Language Act in Europe and Hungary by dr. Ádám Kósa

Nutrient profiles for foods bearing claims

508 the number of suicide deaths in deaths per 100,000 people was the suicide rate in Suicide deaths in 2013 by gender

Injecting trends in Austria including results of a systematic literature review on interventions aiming to influence the route of administration

Tuberculosis Now! Jon S Friedland MA, FRCPE, FMedSci. Infectious Diseases & Immunity

State of SUDEP Guidelines Development and Other Opportunities to Advance Best Practices June 24, 2012

Differences make a Difference

Transcription:

Antonio Gil-Nagel Programa de epilepsia Hospital Ruber Internacional, Madrid Centro de Tecnología Biomédica Universidad Politécnica de Madrid

Prevalence of epilepsy: 8.93/1,000 (WHO 1 ) Europe population in 2010: 711 million 2 People with epilepsy in Europe: 6,350,000 25 to 30% are refractory 2 : 1.6 to 1.9 million patients 1. Epilepsy atlas. WHO 2005 2. Wikipedia 3. Kwan and Brodie. New Engl J Med 2000

Beyond seizure recurrence, epilepsy poses a burden in multiple aspects of life: Biological Psychological Educational Social Employment, This burden is more severe in refractory epilepsy Sillanpäa et al; NEJM 1998

Depression in epilepsy Type of study Authors Rate of depression General population Boyd, Weissman. 1982 Men: 1-3% Women: 2-9% Epilepsy patients: Community based studies Jacoby et al. 1996 Edeh, Toone. 1987 and 1990 Hospital based studies Roy. 1979 Robertson et al. 1994 Victoroff et al. 1994 9-22% 27-58% The rate of depression is higher in patients with refractory compared to controlled epilepsy 1 Concomitant depression is a risk factor for refractory epilepsy 2 Depression but not seizure frequency predicts QOL in refractory epilepsy 3 1. Victoroff et al; Arch Neurol 1994 2. Hitiris et al; Epilepsy Res 2007 3. Boylan et al; Neurology 2004

Mortality in epilepsy 1.6-9.3 times higher than general population 1 Epilepsy related causes of death account for 40% 2. These include: Accidents Status epilepticus Sudden Unexpected Death in Epilepsy: 17% deaths, 1% every year in severe cases 50.000 deaths per year in the USA directly related to epilepsy 1. Cockerell et al, Lancet 1994 2. Téllez-Zenteno JF, et al; Epilepsy Res 2005

Incidence (per 1,000 persons-year) in prospective studies: Medically refractory epilepsy 1,2 : 3.5 to 3.8 Epilepsy surgery referals 3 : 9.0 Surgical candidates not operated 4 : 6.3 Persisting seizures after surgery 5 : 6.3 1. Leestma et al. Epilepsia 1997 2. Racoosin et al. Neurology 2001 3. Dasheiff et al. J Clin Neurohys 1991 4. Nilsson et al. Epilepsia 2003 5. Sperling et al. Epilepsia 2005

Patients who fail their first drug due to inefficacy have a low probability of future success (32%) 1 Other risk factors 1,2,3 : Partial/focal epilepsy (80%) High seizure frequency before diagnosis Abnormal EEG Abnormal MRI Generalised symptomatic epilepsy Developmental delay 1. Kwan and Brodie. New Engl J Med 2000 2. Callaghan et al. Epilepsia 2005 3. Semah et al, Neurology1998

Antiepileptic drugs have limited impact on refractory epilepsy % seizure free patients 61 8% Efficacy of sequential therapies 41 7% 16,6% Number of AEDs, excluding those discontinued because of adverse events 0% 1 2 3-6 7 y 8 Schiller and Najjar, Neurology 2008

Cost of epilepsy in Europe No of people with active epilepsy: 3.4 million Estimated cost: 2,000 to 11,500 per patient/year Estimated total cost of epilepsy in Europe in 2004: 15.5 billion Cost in adjusted for Purchasing Power Parity (PPP) Pugliatti M et al. Epilepsia 2007

Superiority of surgical treatment in some epilepsies

Medical Surgical Superiority of surgical treatment in some epilepsies Best and worst scenario in different studies

Results of QOLIE-89: 40 patients treated with anterior temporal lobectomy vs 40 treated medically. Surgical group p< 0.001 Medical group Wiebe et al; NEJM 2001 Similar results reported by: Markand et al. Epilepsia 2000 Lowe et al. Epilepsia 2004 and others

Depression after surgery Hamid H, et al; Neurology 2011

GTC seizures and their frequency 1,7,9 Duration of epilepsy 2,7,9 and early onset 8 Absence of treatment and poor compliance 11,12 Polytherapy 2,3,9 Intellectual disability 4,9 Seizures during sleep 5,10 Sudden atonic fall during CP seizure 6 Carbamazepine therapy 7 After successful epilepsy surgery death rates are similar to general population 13 1. Timmings et al. Seizure 1993 2. Nilsson et al. Lancet 1999 3. Beran et al. Seizure 2004 4. Jick et al. Phamacoepidemiol Drug Safety 2004 5. Opeskin et al. Epilepsia 1999 6. Rocamora et al. Epilepsia 2003 7. Langan et al. Neurology 2005 8. Hitiris et al. Epilepsy Behav 2007 9. Walczak et al. Neurology 2001 10. Kloster et al. J Neurol Neurosurg Psych 1999 11. George and Davis. J Forensic Sci 1998 12. Williams et al. J Neurol Neurosurg Psych 2003 13. Sperling et al. Epilepsia 2005

Health care cost decline after successful epilepsy surgery Decline in seizure related cost from $2,068 2,094 to $582 in seizure free patients Langfitt et al, Neurology 2007

ILAE Consensus. Definition refractory epilepsy Failure of adequate trials of two tolerated and appropriately chosen and used AEDs (whether as monotherapies or in combination) to achieve sustained seizure freedom. Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy. Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2009

For many years different definitions have been very close in the concept of refractory epilepsy Persistence of seizures after 1 year 1 Seizures of sufficient frequency and severity after 2 years 2 Persistence after highest tolerated dose of AED 3 Persistence after use of potentially effective AEDs 4 2 monotherapies and 1combination 5 1 year or 2-3 AEDs 6 1. Leppik, 1992 2. Jallon, 1997 3. Wolf, 1994 4. Burgeois, 2001 5. Sánchez, 2002 6. Arzimanoglou and Ryvlin, 2008

Current situation: Duration of Epilepsy Prior to Surgical Evaluation Author Area Epilepsy Duration Halasz Hungary 15 years Kumlien Sweden 15.3 years Gil-Nagel Madrid 19 years Wiebe Toronto 22 years No definition has ever said that we should wait very long However, clinicians often wait 20 years before referring patients for epilepsy surgery 1,2 1. Berg et al. Neurology 2003 2. Benbadis et al. Seizure 2003

Attitude of neurologists to epilepsy surgery 1. Survey to 69 hospitals and 14 neurology clinics treating patients with epilepsy, excluding those performing surgery. Physicians considerations: No experience: 38% Reduces seizure frequency: 61% Improves QOL: 53% Cost effective: 92% 2. Referrals for epilepsy surgery evaluation obtained from computerized nationwide database: 88 candidates to surgery 40 referred 15 considered but not referred 33 not considered 1. Kulien E and Mattson P; Seizure 2010 2. de Flon et al; Eur J Neurol 2010

Variability in access to epilepsy surgery Comparing 1998 to 2009 there were no changes in epilepsy surgery in USA despite 1,2 Increase in access to video-eeg monitoring Published guidelines by AAN Higher rate of utilization in 2 : White people Patients with private insurance 1. Englot DJ, et al; Neurology 2012 2. Schiltz NK, et al; Epilepsy Research 2013

Available resources Atlas of Epilepsy Care Around the World ILAE and WHO, 2005 11% countries do not have epilepsy specialists 33.3% countries do not have access to epilepsy surgery Medical specialists involved in epilepsy (per 100,000 pop) Adult neurologists 0.33 Pediatric neurologists 0.14 Neurosurgeons 0.04 Training in epileptology available in 31.8% countries Professional organization in epilepsy available in 91.1% countries

Survey. European Epilepsy Monitoring Association 231 centers identified. Questionnaire returned: 47 centers of 16 countries Video-EEG and intracranial recordings performed in all of them All covered by NHS, in different modalities: Covered within the hospital budget Flat fee per patient (differences within the same country) Fee per day of monitoring (differences within the same country) Only one lifetime evaluation per patient allowed in one country Limited or no coverage by private insurance companies in 7 patients: No coverage of electrodes No coverage of intracranial studies Italy, France, Germany, Netherlands, Spain, Portugal, Czech Republic, United Kingdom, Austria, Norway, Denmark, Turkey, Hungary, Cyprus, Israel, Belgium

Survey of Central Europe Epilepsy Experts Working Group. J Jedrzejczak et al; Seizure 2013 Questionnaire sent to 10 experts: Bulgaria, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, Slovakia and Slovenia. No epilepsy surgery centers in 3 countries, 2 of these reimbursed patients operated in other countries. Waiting time from presurgical evaluation to time of surgery: Less than 6 months in 7 countries 2-3 years in 2 countries Surgery not available in 1 country Surgeries per million inhabitants/year: 0.95 to 7.60

Epilepsy surgery can improve seizure control, quality of life comorbidity and morbidity in patients with refractory epilepsy Inequalities in access to epilepsy surgery occur within the same country and between different countries Future actions (?): Identify these areas of inequality Homogenize access and quality of surgical evaluation and surgery Improve referrals of patients Demand coverage by private insurances Establish European standard and survey

Comparative epidemiology HIV worldwide UNAIDS 2011, pg: 1-10 32 million HIV infection 1.8 deaths in 2012, down from 2.2 in 2005 516 deaths in the UK in 2008 Health Protection Agency: HIV in the United Kingdom, 2010 report HIV worldwide UNAIDS 2011, pg: 1-10

Burden of refractory epilepsy LINCE Study: Health and non-health care resources use in the management of adult outpatients with drug-resistant epilepsy 762 patients, multicentre, epilepsy clinics in Spain Significant increase in the cost ( ): Yearly total: 6,838 (2,000 for controlled epilepsy) Health care: 4,977 Indirect: 1,618 Higher cost in patients with more severe seizures Sancho et al; Epilepsy Res. 2008

Survey mailed to 415 US neurologists. 84 (20%) responses Definition of refractoriness: Proportion of responders (%) Number of monotherapy trials 14 2 52 3 14 4 19 All approved AEDs + Proportion of responders (%) Number of polytherapy trials 9 0 15 1 77 2 15 VNS Other findings: 55% responders considered surgery if Sz frequency >1in 3 months 11% did not discuss epilepsy surgery with their patients VNS: vagus nerve stimulation AS Hakimi et al. Epilepsy and Behavior 2008